Page last updated: 2024-09-02

ecteinascidin 743 and erlotinib hydrochloride

ecteinascidin 743 has been researched along with erlotinib hydrochloride in 1 studies

Compound Research Comparison

Studies
(ecteinascidin 743)
Trials
(ecteinascidin 743)
Recent Studies (post-2010)
(ecteinascidin 743)
Studies
(erlotinib hydrochloride)
Trials
(erlotinib hydrochloride)
Recent Studies (post-2010) (erlotinib hydrochloride)
6601024044,3537863,033

Protein Interaction Comparison

ProteinTaxonomyecteinascidin 743 (IC50)erlotinib hydrochloride (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.1683
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)1.705
Serine/threonine-protein kinase B-raf Mus musculus (house mouse)0.04

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sabbatini, P1

Other Studies

1 other study(ies) available for ecteinascidin 743 and erlotinib hydrochloride

ArticleYear
New agents and new formulations for the treatment of ovarian cancer.
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Dioxoles; Erlotinib Hydrochloride; Female; Humans; Isoquinolines; Ovarian Neoplasms; Predictive Value of Tests; Quinazolines; Recurrence; Remission Induction; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A

2005